Physician profile
Pankaj Kumar
NPI 1285920512
$901.74
in general payments reported to CMS, 2019-2025
16 companies · $886 in 2025
The $886 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.52 · 2025: $886.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $886.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $886.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $241.30 | 2025 | Wegovy, Ozempic |
| Abbvie INC. | $188.54 | 2025 | |
| Pfizer INC. | $184.29 | 2025 | |
| Novartis Pharmaceuticals Corporation | $40.34 | 2025 | |
| Vanda Pharmaceuticals INC. | $39.12 | 2025 | Fanapt, Hetlioz |
| Glaxosmithkline, LLC. | $35.34 | 2025 | Trelegy Ellipta, Shingrix |
| Neurocrine Biosciences, INC. | $29.37 | 2025 | |
| Lundbeck LLC | $19.18 | 2025 | Vyepti |
| Collegium Pharmaceutical, INC. | $18.38 | 2025 | Belbuca |
| Grifols USA, LLC | $16.17 | 2025 | Xembify |
| Zyla Life Sciences, INC. | $15.52 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $15.38 | 2025 | Breztri |
| Aimmune Therapeutics, INC. | $15.30 | 2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.90 | 2025 | Xifaxan |
| Shield Therapeutics INC | $14.32 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $14.29 | 2025 | The Cologuard Plus Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pankaj Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.